PARP inhibitors have been approved for use in breast cancer subtypes that exhibit homologous recombination deficiency (HRD) and ovarian cancer irrespective of HRD status. Because HRD is observed in many tumour types other than ovarian and breast cancer [1-3], PARP inhibition is also being explored in several other tumour types including prostate, pancreatic, lung, gastric and several other cancers. For many of these indications, stratifying patients with HRD seems key to improving treatment outcomes.
Clinical activity is often assessed using intermediate endpoints between progression-free survival and overall survival. Click here to find out more use about intermediate endpoints.